GOLD COPD Exacerbation History Categories and Disease Outcomes
2024

GOLD COPD Exacerbation History and Disease Outcomes

Sample size: 2291 publication 10 minutes Evidence: moderate

Author Information

Author(s): Waeijen-Smit Kiki MSc, Peerlings Daphne E. M. MSc, Jörres Rudolf A. MD PhD, Watz Henrik PhD, Bals Robert PhD, Rabe Klaus F. PhD, Vogelmeier Claus F. PhD, Speicher Tim MSc, Spruit Martijn A. PhD, Simons Sami O. MD PhD, Houben-Wilke Sarah PhD, Franssen Frits M. E. MD PhD, Alter Peter MD PhD

Primary Institution: Department of Research and Development, Ciro, Horn, the Netherlands

Hypothesis

How accurate are exacerbations of chronic obstructive pulmonary disease (ECOPD) history categories by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) in estimating moderate and severe ECOPD and all-cause mortality in patients with COPD?

Conclusion

The study suggests that GOLD ECOPD history categories may be limited in estimating future COPD outcomes, but lowering the threshold for moderate ECOPD may improve performance.

Supporting Evidence

  • GOLD ECOPD history categories had an AUROC of 0.63 for moderate and 0.62 for severe ECOPD.
  • Patients with 3 or more previous moderate ECOPD were more likely to die compared to those without prior ECOPD.
  • Lowering the threshold for moderate ECOPD may improve performance in estimating future outcomes.

Takeaway

This study looked at how well certain COPD history categories predict future health problems. It found that the current categories might not work well, but changing the rules a bit could help.

Methodology

This cohort study analyzed data from patients with COPD in the COSYCONET study, using binomial logistic regressions and area under the receiver operating characteristic curves (AUROCs) to assess risks.

Potential Biases

Self-reporting of ECOPD events may introduce bias in the data collected.

Limitations

The study relied on self-reported ECOPD data, which may be subject to individual interpretation, and had a cross-sectional approach with only 36% of patients having complete data.

Participant Demographics

Mean age of participants was 65 years, with 60.9% male.

Statistical Information

P-Value

p<0.001

Confidence Interval

95% CI, 0.60-0.65

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1001/jamanetworkopen.2024.45488

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication